Delhi HC: AIIMS to resume dispensation of medicines from pharmacy without delay

The Delhi High Court has asked the All India Institute of Medical Sciences (AIIMS) to make sure that dispensation of medicines from its pharmacy which was functioning limited due to the lockdown to resume without any delay.

Delhi High Court order came on a PIL which stated that non-coronavirus patients who had come for treatment at AIIMS from different ststaion are unable to get medication from the hospital’s pharmacy due to the lockdown.
Rachna Malik, the petitioner also claimed that patients were there was no endorsement on their OPD cards permitting dispensation of medicines as the OPD of AIIMS was closed due to COVID-19 lockdown.

In reply, AIIMS answered the court that its pharmacy has been made fully functional since May 6 and it operates from 10.00 am to 5.00 pm. AIIMS would devise a methodology to enable patients to obtain medicines from the pharmacy, in all such cases, where the medication prescribed requires continuous administration.
A bench of justices Vipin Sanghi and Rajnish Bhatnagar asked AIIMS on the particular issue and asked to file a compliance report before May 14, on the next date of hearing.

  • Related Posts

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    BMJ Research Forum all set to mull over in Delhi on September 5 New Delhi: Research in healthcare in India is a dime a dozen. But the real question that…

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Dr Rajendra Pratap Gupta gets nominated to advise UN Secretary General Geneva/ New Delhi: Former advisor to Union Health Minister of India JP Nadda in his earlier stint and a…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre